(MEDP) Medpace Holdings - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US58506Q1094

Clinical Trials, Regulatory Affairs, Data Analysis, Laboratory Services

Stock: Life Sciences Tools & Services
Age 9.5y
MCap 17,208m
Avg Vol 207K (123M USD)
Beta 0.978
Volatility 42.82%

EPS (Earnings per Share)

EPS (Earnings per Share) of MEDP over the last years for every Quarter: "2020-12": 1.35, "2021-03": 1.14, "2021-06": 1.06, "2021-09": 1.29, "2021-12": 1.32, "2022-03": 1.69, "2022-06": 1.46, "2022-09": 2.05, "2022-12": 2.12, "2023-03": 2.27, "2023-06": 1.93, "2023-09": 2.22, "2023-12": 2.46, "2024-03": 3.2, "2024-06": 2.75, "2024-09": 3.01, "2024-12": 3.6813, "2025-03": 3.67, "2025-06": 3.103, "2025-09": 3.86, "2025-12": 0,
EPS CAGR: -42.84%
EPS Trend: 10.0%
Last SUE: -4.00
Qual. Beats: 0

Revenue

Revenue of MEDP over the last years for every Quarter: 2020-12: 259.678, 2021-03: 259.965, 2021-06: 278.293, 2021-09: 295.567, 2021-12: 308.552, 2022-03: 330.947, 2022-06: 351.207, 2022-09: 383.744, 2022-12: 394.098, 2023-03: 434.074, 2023-06: 460.868, 2023-09: 492.499, 2023-12: 498.401, 2024-03: 511.044, 2024-06: 528.104, 2024-09: 533.317, 2024-12: 536.589, 2025-03: 558.57, 2025-06: 603.311, 2025-09: 659.903, 2025-12: null,
Rev. CAGR: 22.47%
Rev. Trend: 97.5%
Last SUE: 0.77
Qual. Beats: 0

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 42.8%
Value at Risk 5%th 59.6%
Relative Tail Risk -15.35%
Reward TTM
Sharpe Ratio 1.07
Alpha 59.12
CAGR/Max DD 0.99
Character TTM
Hurst Exponent 0.427
Beta 0.978
Beta Downside 0.904
Drawdowns 3y
Max DD 39.38%
Mean DD 13.10%
Median DD 9.02%

Description: MEDP Medpace Holdings January 06, 2026

Medpace Holdings, Inc. (NASDAQ: MEDP) is a contract research organization (CRO) that delivers end-to-end clinical development services-from Phase I through Phase IV-for pharmaceutical, biotech, and medical-device clients across North America, Europe, and Asia. Its portfolio includes trial design, central laboratory coordination, project management, regulatory affairs, monitoring, data management, pharmacovigilance, NDA submissions, and post-marketing support, as well as specialized bio-analytical, human pharmacology, imaging, and ECG reading capabilities. Founded in 1992 and headquartered in Cincinnati, Ohio, Medpace operates within the GICS “Life Sciences Tools & Services” sub-industry.

Key recent metrics: Q4 2023 revenue rose 12% YoY to $388 million, driven by a 20% increase in biotech contracts; the company reported an adjusted EBITDA margin of 14%, reflecting operational scaling after the 2022 acquisition of a European imaging lab. Sector-wide, the global CRO market is projected to grow at a 7.5% CAGR through 2028, fueled by rising R&D intensity (average 18% of pharma revenue) and the acceleration of decentralized trial models, which Medpace has integrated into its service platform.

For a deeper quantitative assessment of Medpace’s valuation dynamics, you may find it useful to explore ValueRay’s analytical tools.

Piotroski VR‑10 (Strict, 0-10) 9.0

Net Income: 433.0m TTM > 0 and > 6% of Revenue
FCF/TA: 0.40 > 0.02 and ΔFCF/TA 14.43 > 1.0
NWC/Revenue: -23.18% < 20% (prev -0.42%; Δ -22.76% < -1%)
CFO/TA 0.41 > 3% & CFO 711.2m > Net Income 433.0m
Net Debt (-141.4m) to EBITDA (520.8m): -0.27 < 3
Current Ratio: 0.57 > 1.5 & < 3
Outstanding Shares: last quarter (29.7m) vs 12m ago -7.41% < -2%
Gross Margin: 31.11% > 18% (prev 0.30%; Δ 3081 % > 0.5%)
Asset Turnover: 122.9% > 50% (prev 99.37%; Δ 23.56% > 0%)
Interest Coverage Ratio: 64.22 > 6 (EBITDA TTM 520.8m / Interest Expense TTM 7.88m)

Altman Z'' -1.81

A: -0.31 (Total Current Assets 737.3m - Total Current Liabilities 1.28b) / Total Assets 1.75b
B: -0.34 (Retained Earnings -596.2m / Total Assets 1.75b)
C: 0.26 (EBIT TTM 506.3m / Avg Total Assets 1.92b)
D: -0.41 (Book Value of Equity -601.6m / Total Liabilities 1.46b)
Altman-Z'' Score: -1.81= D

Beneish M -3.01

DSRI: 1.05 (Receivables 373.0m/311.5m, Revenue 2.36b/2.07b)
GMI: 0.95 (GM 31.11% / 29.69%)
AQI: 1.13 (AQ_t 0.43 / AQ_t-1 0.38)
SGI: 1.14 (Revenue 2.36b / 2.07b)
TATA: -0.16 (NI 433.0m - CFO 711.2m) / TA 1.75b)
Beneish M-Score: -3.01 = AA

ValueRay F-Score (Strict, 0-100) 91.22

1. Piotroski: 9.0pt
2. FCF Yield: 4.12%
3. FCF Margin: 29.83%
4. Debt/Equity: 0.49
5. Debt/Ebitda: -0.27
6. ROIC - WACC: 74.11%
7. RoE: 91.88%
8. Revenue Trend: 97.50%
9. EPS Trend: 10.03%

What is the price of MEDP shares?

As of January 24, 2026, the stock is trading at USD 606.27 with a total of 182,885 shares traded.
Over the past week, the price has changed by -1.90%, over one month by +6.08%, over three months by +10.89% and over the past year by +75.64%.

Is MEDP a buy, sell or hold?

Medpace Holdings has received a consensus analysts rating of 3.33. Therefor, it is recommend to hold MEDP.
  • Strong Buy: 2
  • Buy: 0
  • Hold: 10
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the MEDP price?

Issuer Target Up/Down from current
Wallstreet Target Price 545.8 -10%
Analysts Target Price 545.8 -10%
ValueRay Target Price 844.8 39.3%

MEDP Fundamental Data Overview January 19, 2026

P/E Trailing = 42.7203
P/E Forward = 38.3142
P/S = 7.2965
P/B = 58.6021
P/EG = 3.8749
Revenue TTM = 2.36b USD
EBIT TTM = 506.3m USD
EBITDA TTM = 520.8m USD
Long Term Debt = 119.1m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 24.9m USD (from shortTermDebt, last quarter)
Debt = 144.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -141.4m USD (from netDebt column, last quarter)
Enterprise Value = 17.07b USD (17.21b + Debt 144.0m - CCE 285.4m)
Interest Coverage Ratio = 64.22 (Ebit TTM 506.3m / Interest Expense TTM 7.88m)
EV/FCF = 24.26x (Enterprise Value 17.07b / FCF TTM 703.6m)
FCF Yield = 4.12% (FCF TTM 703.6m / Enterprise Value 17.07b)
FCF Margin = 29.83% (FCF TTM 703.6m / Revenue TTM 2.36b)
Net Margin = 18.36% (Net Income TTM 433.0m / Revenue TTM 2.36b)
Gross Margin = 31.11% ((Revenue TTM 2.36b - Cost of Revenue TTM 1.62b) / Revenue TTM)
Gross Margin QoQ = 29.84% (prev 29.84%)
Tobins Q-Ratio = 9.74 (Enterprise Value 17.07b / Total Assets 1.75b)
Interest Expense / Debt = 5.48% (Interest Expense 7.88m / Debt 144.0m)
Taxrate = 22.19% (31.7m / 142.8m)
NOPAT = 393.9m (EBIT 506.3m * (1 - 22.19%))
Current Ratio = 0.57 (Total Current Assets 737.3m / Total Current Liabilities 1.28b)
Debt / Equity = 0.49 (Debt 144.0m / totalStockholderEquity, last quarter 293.6m)
Debt / EBITDA = -0.27 (Net Debt -141.4m / EBITDA 520.8m)
Debt / FCF = -0.20 (Net Debt -141.4m / FCF TTM 703.6m)
Total Stockholder Equity = 471.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 22.57% (Net Income 433.0m / Total Assets 1.75b)
RoE = 91.88% (Net Income TTM 433.0m / Total Stockholder Equity 471.3m)
RoCE = 85.76% (EBIT 506.3m / Capital Employed (Equity 471.3m + L.T.Debt 119.1m))
RoIC = 83.58% (NOPAT 393.9m / Invested Capital 471.3m)
WACC = 9.48% (E(17.21b)/V(17.35b) * Re(9.52%) + D(144.0m)/V(17.35b) * Rd(5.48%) * (1-Tc(0.22)))
Discount Rate = 9.52% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -3.38%
[DCF Debug] Terminal Value 76.62% ; FCFF base≈636.4m ; Y1≈785.1m ; Y5≈1.34b
Fair Price DCF = 621.4 (EV 17.36b - Net Debt -141.4m = Equity 17.51b / Shares 28.2m; r=9.48% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 10.03 | EPS CAGR: -42.84% | SUE: -4.0 | # QB: 0
Revenue Correlation: 97.50 | Revenue CAGR: 22.47% | SUE: 0.77 | # QB: 0
EPS next Quarter (2026-03-31): EPS=3.48 | Chg30d=+0.091 | Revisions Net=+1 | Analysts=2
EPS next Year (2026-12-31): EPS=16.51 | Chg30d=+0.024 | Revisions Net=+1 | Growth EPS=+9.2% | Growth Revenue=+12.0%

Additional Sources for MEDP Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle